Cyclerion Therapeutics Inc
$ 1.35
-2.17%
26 Dec - close price
- Market Cap 5,138,400 USD
- Current Price $ 1.35
- High / Low $ 1.37 / 1.30
- Stock P/E N/A
- Book Value 2.58
- EPS -0.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -0.25 %
- 52 Week High 6.25
- 52 Week Low 1.28
About
Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on discovering and developing innovative therapies for serious central nervous system (CNS) disorders. Leveraging its proprietary technology platform, Cyclerion is advancing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs in cognitive impairment and other CNS diseases. The company's strategic commitment to enhancing treatment options in the neurotherapeutics arena positions it as a compelling investment opportunity for institutional investors interested in pioneering advancements in the biopharmaceutical landscape.
Analyst Target Price
$4.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-05 | 2025-05-05 | 2025-03-03 | 2024-11-11 | 2024-08-07 | 2024-05-07 | 2024-03-05 | 2023-11-13 | 2023-07-28 | 2023-05-12 | 2023-03-22 |
| Reported EPS | -0.3 | -0.11 | -0.5591 | 0.2082 | -0.2862 | -0.5267 | -0.6183 | -0.6847 | 3.1072 | -1.8322 | -3.1957 | -0.17 |
| Estimated EPS | 0 | None | None | None | None | None | None | None | None | -0.28 | -0.3 | -0.29 |
| Surprise | -0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.5522 | -2.8957 | 0.12 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | -554.3571% | -965.2333% | 41.3793% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYCN
2025-12-02 05:22:16
Cyclerion Therapeutics announced a $1.0 million milestone payment from Akebia on December 1, 2025. This payment is triggered by Akebia initiating Phase 2 trials for FSGS treatment with Praliciguat, with the first patient dosing in the U.S. expected in 2026.
2025-11-24 05:22:16
Cyclerion Therapeutics, Inc. has reported a flat financial performance for the quarter ending June 2025, showing both strengths like peak operating cash flow and challenges such as high debt levels. The microcap company in the Pharmaceuticals & Biotechnology sector is grappling with significant operating losses and market volatility, resulting in a year-to-date stock return of -55.90% compared to the S&P 500's positive return. These mixed results have led to a revision in its stock evaluation.
2025-11-19 07:07:25
Cyclerion Therapeutics, Inc. has released its Q3 2025 10-Q report, detailing a 441% increase in total revenues to $1.049 million, driven by a purchase agreement with Akebia, and a 24% decrease in net loss to $(2.729) million due to insurance recovery. The company is focusing on an individualized therapy for treatment-resistant depression (TRD) and has secured a license agreement with MIT for this product. Strategic initiatives include cost reduction through consultants, leadership changes, fundraising for TRD product plans, and ongoing clinical trials for zagociguat.
2025-09-24 14:03:00
Cyclerion Therapeutics (NASDAQ: CYCN) is seeing increased investor optimism due to recent advancements in its treatment pipeline, with stocks trading up by 9.6%. The company has signed a licensing agreement with MIT to focus on neuropsychiatric disorders, particularly treatment-resistant depression, with pilot programs set for 2026. While the company faces operating losses, a strong current ratio indicates liquidity for R&D, and the success of upcoming Phase 2 trials will be critical in determining its future financial stability and market position.
2025-09-23 23:02:00
Cyclerion Therapeutics stock surged nearly 50% after-hours following the announcement of its relaunch as a neuropsychiatric company. This strategic shift includes a new licensing agreement with MIT and a lead program targeting treatment-resistant depression, with a Phase 2 trial expected in 2026. The news generated significant bullish sentiment among retail investors on Stocktwits.
2025-09-23 22:09:10
Cyclerion Therapeutics has entered a licensing agreement with MIT for intellectual property related to treatment-resistant depression, marking a strategic relaunch into neuropsychiatric treatments. The company plans to use anesthetic agents with a proprietary technology to resynchronize brain communication and intends to initiate a Phase 2 trial in 2026. This move has generated investor optimism, with the company’s stock surging over 24% in the past week.
